Jilin Aodong Pharmaceutical Group Co (SZSE:000623) Net Income From Continuing Operations : ¥1,903 Mil (TTM As of Mar. 2025)

View and export this data going back to 1996. Start your Free Trial

What is Jilin Aodong Pharmaceutical Group Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Jilin Aodong Pharmaceutical Group Co's net income from continuing operations for the three months ended in Mar. 2025 was ¥517 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was ¥1,903 Mil.

Jilin Aodong Pharmaceutical Group Co Net Income From Continuing Operations Historical Data

The historical data trend for Jilin Aodong Pharmaceutical Group Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jilin Aodong Pharmaceutical Group Co Net Income From Continuing Operations Chart

Jilin Aodong Pharmaceutical Group Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income From Continuing Operations

Get a 7-Day Free Trial

1,691.41

1,770.86

1,801.01

1,444.34

1,519.19

Jilin Aodong Pharmaceutical Group Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Income From Continuing Operations	Get a 7-Day Free Trial															132.65	385.47	700.43	300.65	516.51

Jilin Aodong Pharmaceutical Group Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,903 Mil.

Jilin Aodong Pharmaceutical Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jilin Aodong Pharmaceutical Group Co Ltd (SZSE:000623) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

N/A

Address

No. 2158, Jidong Street, Dunhua, CHN, 133700

Website

http://www.jlaod.com

Jilin Aodong Pharmaceutical Group Co Ltd is engaged in manufacturing of pharmaceuticals. Its products include Anshen Bunao Liquid, Antelope Cough Syrup, Yangxue Yin Oral Liquid, Xinnao Shutong Capsule, Calf Spleen Extract Injection, Xuefu Zhuyu Oral Liquid, and others.

Executives

Guo Shu Qin	Directors, executives
Li Xiu Lin	Director
Wang Zhen Yu	Directors, Directors, and Executives
Zhao Da Long	Director
Yang Kai	Directors, executives
Zhang Shu Yuan	Directors, executives
Chen Yong Feng	Supervisors
Zhang Ming Jing	Supervisors
Li An Ning	Supervisors
Lin Xiao Lin	Executives
Ying Gang	Director
Guo Li	Supervisors
Xu Dong Lin	Supervisors
Zhu Yan	Directors, executives
Li Li Ping	Supervisors

Jilin Aodong Pharmaceutical Group Co Headlines

No Headlines